Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00202865
Other study ID # P04352
Secondary ID 2472
Status Completed
Phase Phase 3
First received September 16, 2005
Last updated March 22, 2017
Start date May 1, 2005
Est. completion date May 1, 2007

Study information

Verified date March 2017
Source Merck Sharp & Dohme Corp.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, multi-center, placebo-controlled study with two parallel treatment groups (placebo and infliximab) in subjects with ankylosing spondylitis (AS) to evaluate the efficacy of infliximab 3 mg/kg.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date May 1, 2007
Est. primary completion date May 1, 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Are men or women >=18 years of age at Screening.

- Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation), and must continue such precautions for 6 months after receiving the last study agent infusion, and have a negative serum pregnancy test prior to enrollment. Additionally, male subjects who are sexually active, with women of childbearing potential, should ensure that they or their partners are using adequate contraception

- Have had a diagnosis of AS according to the modified 1984 New York criteria, prior to Screening.

- Have active disease, as evidenced by a BASDAI score of >=4 at Baseline and at Screening

- Screening tests must meet the following criteria:

- Hemoglobin: >=9.0 g/dL (5.6 mmol/L) for men and >=8.5 g/dL (5.3 mmol/L) for women

- Serum transaminase levels must be within 3 times the ULN

- Serum creatinine <=1.4 mg/dL (107umol/L).

- Are capable of reading and understanding subject assessment forms and providing written informed consent.

- Have had a documented negative reaction to a PPD skin test (PPD induration < 5 mm) performed within 1 month prior to the first study infusion. If PPD negative, chest x-ray still required.

- Subjects must understand English or French.

Exclusion Criteria:

- Have had a serious infection (eg, sepsis, hepatitis, abscesses, pneumonia, or pyelonephritis), have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 8 weeks prior to randomization. Less serious infections (eg, acute upper respiratory tract infection, or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator.

- Have ever had a chronic or recurrent infectious disease including, but not limited to, chronic renal infection, chronic chest infection (eg, bronchiectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), open, draining, or infected skin wound, or ulcer.

- Have ever had opportunistic infections (eg, herpes zoster (shingles), cytomegalovirus, pneumocystis carinii, aspergillosis, histoplasmosis)

- Have had documented an atypical mycobacteria infection.

- Have had active TB or recent close contact with an individual with active TB or ever had evidence of latent TB.

- Have a chest radiograph (PA and lateral) that displays granulomas or apical fibronodular disease suggestive of previous TB as determined by the investigator.

- Have documented Hepatitis B (surface antigen positive).

- Have documented HIV.

- Have a known malignancy or history of malignancy within 5-year period prior to Screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence). Have a history of lymphoproliferative disease including lymphoma, have multiple sclerosis, or other central demyelinating disorder, or have congestive heart failure.

- Have a serious concomitant illness, other than the ones mentioned above, that might interfere with participation in the trial.

- Have a known allergy to murine proteins or other chimeric proteins.

- Have ever received any previous treatment with infliximab, etanercept or other anti-TNF agents prior to first study infusion.

- Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.

- Have a contraindication to any study protocol component.

- Subjects who have a contraindication to the MRI component of the study can be enrolled, however, they will be exempt from all MRI examinations.

- Subjects with unstable doses of NSAIDS, DMARDs, analgesics or corticosteroids at Screening who will continue to receive these medications during the study.

- Subjects who are receiving >10 mg of prednisone (or equivalent) daily.

- Have a documented history of fibromyalgia confirmed by an appropriate physician specialist (ie, rheumatologist).

- Have had a documented history of total ankylosis.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
infliximab
Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
Placebo
Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Inman RD, Maksymowych WP; CANDLE Study Group.. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010 Jun;37(6):1203-10. doi: 10.3899/jrheum.091042. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of AS assessment responders ASAS20 (ie, a minimum 20% improvement from Baseline according to the ASAS response criteria) at Week 12. Week 12
Secondary Change from Baseline in the magnetic resonance imaging activity score at Week 12. Week 12
Secondary Change from Baseline in BASFI at Week 12 and Week 50. Week 12 and Week 50
Secondary Change from Baseline in BASDAI at Week 12 and Week 50. Week 12 and Week 50
Secondary Change from Baseline in BASGI at Week 12 and Week 50. Week 12 and Week 50
Secondary Change from Baseline in spinal mobility (BASMI) at Week 12 and Week 50. Week 12 and Week 50
Secondary Change from Baseline in spinal mobility (EDASMI) at Week 12 and Week 50. Week 12 and Week 50
Secondary Proportion of subjects achieving an ASAS40 at Week 12 and Week 50. Week 12 and Week 50
Secondary Proportion of subjects achieving an ASAS50 at Week 12 and Week 50. Week 12 and Week 50
Secondary Proportion of subjects achieving an ASAS70 at Week 12 and Week 50. Week 12 and Week 50
Secondary Change from Baseline in the physical component of the SF-36 at Week 12 and Week 50. Week 12 and Week 50
Secondary Assess the treatment survival. From baseline to week 50
Secondary Quantify the number of subjects requiring dose titration. Week 22 and 38
Secondary Assess predictors of response. Week 12 and 50
Secondary Assess predictors of toxicity. 50 weeks
See also
  Status Clinical Trial Phase
Completed NCT01208207 - A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108) Phase 3
Completed NCT02509026 - Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA Phase 4
Completed NCT02704845 - Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain N/A
Terminated NCT01209702 - A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs Phase 3
Terminated NCT01209689 - A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy Phase 3
Terminated NCT00766402 - An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Phase 4
Completed NCT00000433 - Blocking Tumor Necrosis Factor in Ankylosing Spondylitis Phase 2
Completed NCT00779935 - Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED) Phase 4
Completed NCT00779012 - A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED) Phase 4
Completed NCT01863732 - Extension in AS: Sustainability of Benefits, Safety and Tolerability Phase 3
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT01567878 - Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects N/A
Completed NCT01188655 - Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis N/A
Completed NCT00760669 - An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants Phase 4
Completed NCT02159053 - 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT02374502 - Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial N/A
Withdrawn NCT00298012 - Methotrexate in the Treatment of Axial Spondyloarthritis Phase 4
Terminated NCT00273858 - Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis N/A
Completed NCT04810715 - Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis
Completed NCT03880968 - Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis